ECOG-ACRIN Office of Communications
Philadelphia, Pa., September 15, 2015 — Raymond C. Bergan, MD, a practicing medical oncologist and internationally regarded researcher known for leading breakthrough studies on how cancer cells spread and preventive treatments for high-risk patients, has been elected as chair of the ECOG-ACRIN Cancer Research Group’s (ECOG-ACRIN) Prevention Committee. Dr. Bergan serves in several leadership roles at Oregon Health & Science University (OHSU) in Portland, Oregon. He is the DeArmond Chair of Cancer Research, chief of the Division of Hematology and Medical Oncology, associate director for Medical Oncology for the OHSU Knight Cancer Institute and professor of Medicine.
The ECOG-ACRIN Prevention Committee develops biomarker-driven trials targeting patients who have been previously successfully treated for a prior cancer yet are at high risk for recurrence, as well as healthy individuals at risk for developing cancer due to the presence of premalignant disease. It uses state-of-the-science preclinical data to inform the development of highly informative phase II and III prevention trials suitable for implementation across the National Cancer Institute’s National Community Oncology Program (NCORP). ECOG-ACRIN is a research base in NCORP.
“Unprecedented advances in technology and biology now allow us to detect cancer at a very early and vulnerable stage,” said Dr. Bergan. “Coupled to the emergence of whole new classes of therapeutic agents, cancer prevention is poised for major advances. I consider it an honor to be able to work with the talented and dedicated members of ECOG-ACRIN to prevent cancer from continuing to steal the lives of the people we know and love.”
Dr. Bergan succeeds Fadlo R. Khuri, MD, formerly of Emory University, who resigned the position earlier this year to become president of the American University of Beirut.
The Prevention Committee is part of ECOG-ACRIN’s Cancer Control and Outcomes Program.